An act relating to reporting on adverse reactions related to immunizations

2025-2026 Regular Session Introduced by Tom Burditt and 11 co-sponsors

H 69 would establish a framework for reporting adverse reactions to immunizations, improving data collection and transparency for vaccine safety in Vermont.

Read first time and referred to the Committee on Human Services

Bill Summary: H 69 (2025-2026) – Vermont

Purpose and intent

H 69 seeks to establish reporting requirements related to adverse reactions associated with immunizations.

The bill appears aimed at improving transparency and data collection about vaccine-related adverse events, potentially informing public health decision-making and oversight.

Key provisions and changes (as introduced)

Create or specify a framework for reporting adverse reactions to immunizations. While the exact language is not provided here, typical components in similar bills include:

Designated entities or individuals responsible for reporting (e.g., healthcare providers, hospitals, pharmacists, manufacturers).
What constitutes an adverse reaction to immunizations (definitions and scope).
Timelines and methods for submitting reports (electronic reporting, reporting forms, frequency).
Data elements required in reports (patient demographics, vaccine type, lot number, date of vaccination, reaction description, severity, outcome).
Criteria for confidentiality and privacy protections around reported data.
Mechanisms for data aggregation, analysis, and public reporting or dashboards.
Possible requirements for state health department oversight, quarterly or annual summaries, and risk communication.

Note: The exact statutory text is not provided in the overview, so the above reflects common features of reporting-related immunization bills and the typical structure such provisions may take.

Who would be affected

Healthcare providers administering vaccines (doctors, nurses, clinics, hospitals, pharmacies) who would be required to report adverse events.

Immunization manufacturers and distributors, depending on the final text.

State health authorities and the Vermont Department of Health, which would collect, analyze, and possibly publish data.

Patients and the general public could gain access to summarized adverse event data, subject to privacy protections.

Procedural and timeline aspects

Action history shows:

January 23, 2025: Read first time and referred to the Committee on Human Services.

This indicates the bill is in the early legislative stage and would proceed through committee review, potential amendments, and floor action in the Vermont General Assembly.

Timeline specifics (e.g., effective date, reporting start date, phase-in periods) would be determined in the final enacted bill. If the bill includes phased compliance, the text would specify dates for implementation.

Potential impacts and considerations

Public health data: Improved surveillance of vaccine safety through more systematic adverse event reporting.

Policy and program decisions: Data could influence vaccine safety communications, risk assessment, and potential policy adjustments.

Privacy and data use: Depending on data elements, the bill would need to balance transparency with patient confidentiality and HIPAA-equivalent state protections.

Administrative burden: Providers and health entities may incur reporting workloads; the bill might include exceptions, thresholds, or streamlined reporting mechanisms to mitigate burden.

Next steps for readers

Monitor committee developments (House Committee on Human Services) for amendments, fiscal notes, and clarifications on definitions, reporting requirements, and enforcement.

Review the final bill text once available to understand specific reporting timelines, data elements, privacy provisions, and any penalties or incentives for compliance.